Key Points
- 01CMS has begun the Medicare GLP-1 Bridge pilot for weight-loss drugs
- 02Eligible Medicare Part D enrollees can access Wegovy, Zepbound and Foundayo
- 03Participants who qualify will pay a $50 monthly cost for these GLP-1 drugs
- 04The temporary pilot runs through December 31, 2027 with set eligibility rules
New Medicare pilot for GLP-1 weight-loss drugs
On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge pilot, a new federal initiative focused on weight-loss medications. The pilot opens a pathway for certain Medicare beneficiaries to obtain newer GLP-1 drugs specifically for obesity treatment under their drug coverage. It marks a significant change from prior limits on Medicare coverage for these medicines when used solely for weight loss.
Under the demonstration, qualifying enrollees can obtain selected brand-name GLP-1 therapies for a fixed cost of $50 per month. This price applies to a defined list of medications included in the pilot rather than to all GLP-1 drugs on the market. The program is set up as a temporary bridge, with the intention of operating for a limited period while data are collected.
Drugs covered and dosing formats
The Medicare GLP-1 Bridge covers three high-profile weight-loss drugs: Wegovy, Zepbound and Foundayo. These products are GLP-1–based therapies that have been used to help people with obesity reduce weight. The pilot includes both pill and injection formulations where applicable, allowing access through different dosing routes for the covered brands.
Reporting specifies that semaglutide, marketed as Wegovy, and tirzepatide, marketed as Zepbound, are part of the offering. Foundayo, an orforglipron-based medicine, is also included. All three are available to eligible participants at the same $50 monthly cost, regardless of whether they are taken orally or injected.
Eligibility criteria and key exclusions
To qualify for the GLP-1 Bridge, individuals must be enrolled in Medicare Part D, the program’s prescription drug benefit. They also must meet clinical health criteria related to obesity, with reporting citing a body mass index of at least 35 as one threshold for severe obesity. The pilot is available to adults who meet these requirements and whose plans participate in the initiative.
The program includes notable exclusions. People who already receive GLP-1 medications covered by Medicare for conditions such as Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge. These conditions may be addressed under existing coverage rules, so the pilot is aimed at those seeking GLP-1 treatment specifically for weight loss who do not already have such coverage.
Timeline and objectives of the GLP-1 Bridge
The Medicare GLP-1 Bridge is explicitly temporary. It is scheduled to run until December 31, 2027, creating a defined window during which eligible beneficiaries can access the covered medications at the pilot’s fixed monthly price. The structure as a time-limited demonstration allows CMS to monitor the program’s performance over this period.
During the pilot, CMS aims to gather information on how expanded access to GLP-1 weight-loss drugs affects older and other eligible adults under Medicare. The data can help evaluate patterns of use, affordability and health outcomes among participants. For beneficiaries who qualify, the program provides a new, lower-cost route to medications that may otherwise be difficult to afford under existing coverage rules.
Key Takeaways
- 01The Medicare GLP-1 Bridge substantially broadens short-term access to selected GLP-1 weight-loss drugs for eligible Medicare Part D beneficiaries.
- 02By standardizing participant costs at $50 per month, the pilot makes high-cost obesity medications more financially predictable for those who qualify.
- 03Strict clinical and coverage-based eligibility rules, including BMI requirements and exclusion of already-covered GLP-1 users, tightly target who benefits.
- 04The program’s scheduled end date of December 31, 2027 underscores its role as a data-gathering demonstration rather than a permanent benefit at this stage.
References